AAPL   330.73 (+2.61%)
MSFT   186.21 (+1.80%)
FB   230.78 (+1.98%)
GOOGL   1,437.36 (+1.63%)
AMZN   2,478.01 (+0.71%)
NVDA   357.77 (+2.02%)
CGC   16.74 (+0.66%)
BABA   219.30 (+0.58%)
MU   54.36 (+6.36%)
GE   8.03 (+3.75%)
TSLA   875.76 (+1.29%)
AMD   53.16 (+1.01%)
T   32.84 (+3.27%)
ACB   13.97 (-1.83%)
F   7.45 (+13.39%)
DIS   125.72 (+1.64%)
NFLX   416.62 (+0.55%)
BAC   28.48 (+6.51%)
BA   209.07 (+13.44%)
AAPL   330.73 (+2.61%)
MSFT   186.21 (+1.80%)
FB   230.78 (+1.98%)
GOOGL   1,437.36 (+1.63%)
AMZN   2,478.01 (+0.71%)
NVDA   357.77 (+2.02%)
CGC   16.74 (+0.66%)
BABA   219.30 (+0.58%)
MU   54.36 (+6.36%)
GE   8.03 (+3.75%)
TSLA   875.76 (+1.29%)
AMD   53.16 (+1.01%)
T   32.84 (+3.27%)
ACB   13.97 (-1.83%)
F   7.45 (+13.39%)
DIS   125.72 (+1.64%)
NFLX   416.62 (+0.55%)
BAC   28.48 (+6.51%)
BA   209.07 (+13.44%)
AAPL   330.73 (+2.61%)
MSFT   186.21 (+1.80%)
FB   230.78 (+1.98%)
GOOGL   1,437.36 (+1.63%)
AMZN   2,478.01 (+0.71%)
NVDA   357.77 (+2.02%)
CGC   16.74 (+0.66%)
BABA   219.30 (+0.58%)
MU   54.36 (+6.36%)
GE   8.03 (+3.75%)
TSLA   875.76 (+1.29%)
AMD   53.16 (+1.01%)
T   32.84 (+3.27%)
ACB   13.97 (-1.83%)
F   7.45 (+13.39%)
DIS   125.72 (+1.64%)
NFLX   416.62 (+0.55%)
BAC   28.48 (+6.51%)
BA   209.07 (+13.44%)
AAPL   330.73 (+2.61%)
MSFT   186.21 (+1.80%)
FB   230.78 (+1.98%)
GOOGL   1,437.36 (+1.63%)
AMZN   2,478.01 (+0.71%)
NVDA   357.77 (+2.02%)
CGC   16.74 (+0.66%)
BABA   219.30 (+0.58%)
MU   54.36 (+6.36%)
GE   8.03 (+3.75%)
TSLA   875.76 (+1.29%)
AMD   53.16 (+1.01%)
T   32.84 (+3.27%)
ACB   13.97 (-1.83%)
F   7.45 (+13.39%)
DIS   125.72 (+1.64%)
NFLX   416.62 (+0.55%)
BAC   28.48 (+6.51%)
BA   209.07 (+13.44%)
Log in

OTCMKTS:IMLFFInMed Pharmaceuticals Stock Price, Forecast & News

$0.28
-0.01 (-3.42 %)
(As of 06/5/2020 01:03 PM ET)
Add
Compare
Today's Range
$0.25
Now: $0.28
$0.32
50-Day Range
$0.13
MA: $0.19
$0.29
52-Week Range
$0.11
Now: $0.28
$0.34
Volume703,449 shs
Average Volume302,825 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-750, a topical cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, cancer, and other disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-750; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
Current SymbolOTCMKTS:IMLFF
CUSIPN/A
CIKN/A
Phone(604) 669-7207

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees4
Next Earnings DateN/A
OptionableNot Optionable

Receive IMLFF News and Ratings via Email

Sign-up to receive the latest news and ratings for IMLFF and its competitors with MarketBeat's FREE daily newsletter.

InMed Pharmaceuticals (OTCMKTS:IMLFF) Frequently Asked Questions

How has InMed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

InMed Pharmaceuticals' stock was trading at $0.1876 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IMLFF shares have increased by 50.3% and is now trading at $0.2820. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of InMed Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for InMed Pharmaceuticals.

What price target have analysts set for IMLFF?

1 brokerages have issued twelve-month price objectives for InMed Pharmaceuticals' shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate InMed Pharmaceuticals' share price to reach $1.00 in the next twelve months. This suggests a possible upside of 254.6% from the stock's current price. View analysts' price targets for InMed Pharmaceuticals.

Has InMed Pharmaceuticals been receiving favorable news coverage?

News coverage about IMLFF stock has trended extremely negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. InMed Pharmaceuticals earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutInMed Pharmaceuticals.

Who are some of InMed Pharmaceuticals' key competitors?

Who are InMed Pharmaceuticals' key executives?

InMed Pharmaceuticals' management team includes the following people:
  • Mr. Eric A. Adams, Pres, CEO & Director (Age 56)
  • Mr. Jeffrey M. Charpentier, CFO & Corp. Sec.
  • Ms. Alexandra D. J. Mancini, Sr. VP of Clinical & Regulatory Affairs
  • Mr. Joshua Blacher, Chief Bus. Officer (Age 46)
  • Dr. Eric C. Hsu, Sr. VP of Preclinical R&D

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the OTCMKTS under the ticker symbol "IMLFF."

How do I buy shares of InMed Pharmaceuticals?

Shares of IMLFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InMed Pharmaceuticals' stock price today?

One share of IMLFF stock can currently be purchased for approximately $0.28.

What is InMed Pharmaceuticals' official website?

The official website for InMed Pharmaceuticals is www.inmedpharma.com.

How can I contact InMed Pharmaceuticals?

The company can be reached via phone at (604) 669-7207.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.